



HOUSE BILL 592: Toxic-Free Medical Devices Act of 2025.

2025-2026 General Assembly

| | | | |
|-----------------------|--|---------------------|----------------------|
| Committee: | House Health. If favorable, re-refer to Rules, Calendar, and Operations of the House | Date: | April 10, 2025 |
| Introduced by: | Reps. Reeder, Rhyne | Prepared by: | Stewart Sturkie |
| Analysis of: | First Edition | | Committee Co-Counsel |

OVERVIEW: House Bill 592 would add Article 19C to Chapter 130A of the General Statutes. The bill would prohibit the manufacture, sale, and distribution of intravenous (IV) solution containers and IV tubing made with Di(2-ethylhexyl) phthalate (DEHP) in North Carolina.

BILL ANALYSIS:

Section 1 of the bill would:

- Present legislative findings.
- Introduce definitions for: DEHP, health care practitioner, intentionally added DEHP, IV solution container, IV tubing, and ortho-phthalate.
- Prohibit:
 - Manufacture, sale, or distribution of IV solution containers made with intentionally added DEHP on or after January 1, 2030.
 - Manufacture, sale, or distribution of IV tubing made with intentionally added DEHP on or after January 1, 2035.
 - Replacement of DEHP with another ortho-phthalate in a new or revised medical device.
 - The unintentional addition of DEHP into an IV solution container or tubing at a quantity at or above 0.1 percent weight per weight.
- Exempt from the prohibitions:
 - Human blood collection and storage bags.
 - Apheresis and cell therapy blood kits and bags, including integral tubing.

Section 2 of the bill would impose an administrative penalty on a person who violates the Article. The penalty would not exceed \$5,000 for each day the Article is violated.

EFFECTIVE DATE: Except as otherwise provided, the act would be effective when it becomes law.

BACKGROUND: DEHP has been linked to health concerns that include interference with hormonal systems in humans and animals, adverse effects on reproductive organs and fertility, and respiratory irritation. Studies have suggested a potential link between DEHP and certain types of cancers.

Kara McCraw
Director



Legislative Analysis
Division
919-733-2578